Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Indication
For the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Upadacitinib may be used as monotherapy or in combination with methotrexate.
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines
Formulation
15mg prolonged-release tablets
Comments
February 2023 - Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines
Link to Advice
Advice Published
12/12/2022
SMC Submission Type
Resubmission
SMC Status
Restricted